Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Pfizer Inc at Citi BioPharma Conference Transcript

Sep 07, 2022 / 02:30PM GMT
Christopher J. Stevo
Pfizer Inc. - Senior VP & Chief IR Officer

All right. Before Andrew and Mikael will get started, I need to read a quick forward-looking statement.

I'd like to point out that our discussion today may include forward-looking statements. Forward-looking statements -- forward-looking information is subject to substantial risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding forward-looking statements is available in our SEC Forms 10-K and 10-Q under Risk Factors and forward-looking Information and factors that may affect future results. Please note, forward-looking statements on today's webcast speak only as of the webcast's original date, and we undertake no obligation to update or revise any of these statements.

Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So welcome back. Thank you, Chris. So delighted to introduce our next speakers from Pfizer. So Chris, Head of IR, you already

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot